NovoCure Limited (NVCR) Market Cap & Valuation Ratios
NovoCure Limited (NVCR) has a market cap of $1.7B and a price-to-sales ratio of 2.4, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NVCRNovoCure LimitedFollow NVCR — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
medical devices · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| NVCR | 1.7 | — | 2.6 | — | -1.5% | +11% | -22% | -42% |
| UFPT | 2.3 | 31.9 | 3.8 | 20.7 | 2.7% | +7% | 15% | 14% |
| INSP | 2.1 | — | 1.9 | 24.3 | 5.7% | +4% | 6% | 7% |
| AXGN | 2.0 | — | 7.7 | — | 0.4% | +24% | -5% | -9% |
| ESTA | 1.9 | — | 8.5 | — | -2.2% | +39% | -8% | -9% |
| BFLY | 1.8 | — | 14.9 | — | -1.6% | +28% | -71% | -106% |
| ATEC | 1.7 | — | 2.7 | 77.8 | 0.1% | +19% | -6% | -11% |
| CNMD | 1.5 | 26.6 | 1.7 | 14.0 | 9.1% | +3% | 8% | 4% |
| BVS | 1.3 | — | 2.5 | 14.3 | 7.5% | +3% | 10% | 10% |
| ENOV | 1.2 | — | 1.1 | 8.1 | 5.2% | +5% | -45% | -31% |
| TNDM | 1.2 | — | 1.3 | — | -2.2% | +4% | -4% | -9% |
| Median of these 10 | 29.2 | 2.6 | 17.5 | 1.6% | +6% | -5% | -9% |
; EV/Sales 2.6 vs. 2.6.
Growth vs. price
each dot a company · hover or tap for valuesNovoCure Limited — questions
- What is NovoCure Limited's market cap?
- $1.7B.
- What is NovoCure Limited's price-to-sales ratio?
- 2.4.
Every figure on this page comes from NovoCure Limited's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.